M

M-J. Ahn

Gyeongsang National University

Publishes on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies. 47 papers and 100 citations.

47Publications

100Total Citations

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment Lung Cancer Research Studies Colorectal Cancer Treatments and Studies Cancer Immunotherapy and Biomarkers

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

LBA53 ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib

Z. Piotrowska, M-J. Ahn, Y.K. Pang et al.|Annals of Oncology|2022

Cited by 21

117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study

Andreas Pircher, Szabolcs Soter, Michael A. W. Eaton et al.|Immuno-Oncology Technology|2024

Cited by 11Open Access

LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)

B.C. Cho, M-J. Ahn, J.H. Kang et al.|Annals of Oncology|2022

Cited by 8Open Access

1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study

B.C. Cho, M-J. Ahn, T.M. Kim et al.|Annals of Oncology|2022

Cited by 8

360P ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib

Zofia Piotrowska, M-J. Ahn, Y-K. Pang et al.|Annals of Oncology|2022

Cited by 7Open Access